Cargando…
A Novel Hair Restoration Technology Counteracts Androgenic Hair Loss and Promotes Hair Growth in A Blinded Clinical Trial
Androgenic alopecia (AGA) is a genetically predetermined condition that occurs as a result of stepwise miniaturization of the dermal papilla. During this process, the hair follicle suffers from increasing malnutrition and eventually dies, causing progressive hair loss. We recently highlighted that H...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9861617/ https://www.ncbi.nlm.nih.gov/pubmed/36675398 http://dx.doi.org/10.3390/jcm12020470 |
_version_ | 1784874886461652992 |
---|---|
author | Thor, Dominik Pagani, Andrea Bukowiecki, Julia Houschyar, Khosrow S. Kølle, Stig-Frederik T. Wyles, Saranya P. Duscher, Dominik |
author_facet | Thor, Dominik Pagani, Andrea Bukowiecki, Julia Houschyar, Khosrow S. Kølle, Stig-Frederik T. Wyles, Saranya P. Duscher, Dominik |
author_sort | Thor, Dominik |
collection | PubMed |
description | Androgenic alopecia (AGA) is a genetically predetermined condition that occurs as a result of stepwise miniaturization of the dermal papilla. During this process, the hair follicle suffers from increasing malnutrition and eventually dies, causing progressive hair loss. We recently highlighted that HIF-1α modulation may counteract hair loss. Here, we aim to demonstrate the positive influence of Tomorrowlabs HIF strengthening factor [HSF] hair restoration technology on hair biology in a monocentric blinded clinical trial over a total period of 9 months. A trial with 20 subjects (4 female and 16 male) and once-daily application of [HSF] hair restoration technology to the scalp was conducted. To assess the tolerability and efficacy of [HSF], testing included dermatological assessment, determination of hair loss by counting after combing, macro images of the head and TrichoScan evaluation of hair density as well as the proportion of anagen hair versus telogen hair. The clinical data show Tomorrowlabs [HSF] hair restoration to be safe and effective to counteract AGA. The use of Tomorrowlabs [HSF] hair restoration resulted in improvements in the clinical parameters of hair quality such as thickness (+7.2%), hair density (+14.3%) and shine and elasticity (+20.3%) during the test period. The effectiveness of the test product was further determined by a significant reduction in hair loss of an average of 66.8% in treatment-responsive subjects after 6 months and an increase in hair growth reaching up to 32.5%, with an average percentage change of 8.4% in all participants and 10.8% in the responsive patients (85% of the study cohort) after 9 months on TrichoScan evaluation. The hair growth cycle was harmonized with the result of an average anagen hair percentage increase of +8.0% and telogen hair percentage reduction of −14.0% shown in the test area. Applicable for both sexes in an alcohol-free formulation, beneficial to scalp health and free of complications or side effects, this novel product provides objectively measurable results counteracting hair loss paired with an improved look and feel of the hair. |
format | Online Article Text |
id | pubmed-9861617 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-98616172023-01-22 A Novel Hair Restoration Technology Counteracts Androgenic Hair Loss and Promotes Hair Growth in A Blinded Clinical Trial Thor, Dominik Pagani, Andrea Bukowiecki, Julia Houschyar, Khosrow S. Kølle, Stig-Frederik T. Wyles, Saranya P. Duscher, Dominik J Clin Med Article Androgenic alopecia (AGA) is a genetically predetermined condition that occurs as a result of stepwise miniaturization of the dermal papilla. During this process, the hair follicle suffers from increasing malnutrition and eventually dies, causing progressive hair loss. We recently highlighted that HIF-1α modulation may counteract hair loss. Here, we aim to demonstrate the positive influence of Tomorrowlabs HIF strengthening factor [HSF] hair restoration technology on hair biology in a monocentric blinded clinical trial over a total period of 9 months. A trial with 20 subjects (4 female and 16 male) and once-daily application of [HSF] hair restoration technology to the scalp was conducted. To assess the tolerability and efficacy of [HSF], testing included dermatological assessment, determination of hair loss by counting after combing, macro images of the head and TrichoScan evaluation of hair density as well as the proportion of anagen hair versus telogen hair. The clinical data show Tomorrowlabs [HSF] hair restoration to be safe and effective to counteract AGA. The use of Tomorrowlabs [HSF] hair restoration resulted in improvements in the clinical parameters of hair quality such as thickness (+7.2%), hair density (+14.3%) and shine and elasticity (+20.3%) during the test period. The effectiveness of the test product was further determined by a significant reduction in hair loss of an average of 66.8% in treatment-responsive subjects after 6 months and an increase in hair growth reaching up to 32.5%, with an average percentage change of 8.4% in all participants and 10.8% in the responsive patients (85% of the study cohort) after 9 months on TrichoScan evaluation. The hair growth cycle was harmonized with the result of an average anagen hair percentage increase of +8.0% and telogen hair percentage reduction of −14.0% shown in the test area. Applicable for both sexes in an alcohol-free formulation, beneficial to scalp health and free of complications or side effects, this novel product provides objectively measurable results counteracting hair loss paired with an improved look and feel of the hair. MDPI 2023-01-06 /pmc/articles/PMC9861617/ /pubmed/36675398 http://dx.doi.org/10.3390/jcm12020470 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Thor, Dominik Pagani, Andrea Bukowiecki, Julia Houschyar, Khosrow S. Kølle, Stig-Frederik T. Wyles, Saranya P. Duscher, Dominik A Novel Hair Restoration Technology Counteracts Androgenic Hair Loss and Promotes Hair Growth in A Blinded Clinical Trial |
title | A Novel Hair Restoration Technology Counteracts Androgenic Hair Loss and Promotes Hair Growth in A Blinded Clinical Trial |
title_full | A Novel Hair Restoration Technology Counteracts Androgenic Hair Loss and Promotes Hair Growth in A Blinded Clinical Trial |
title_fullStr | A Novel Hair Restoration Technology Counteracts Androgenic Hair Loss and Promotes Hair Growth in A Blinded Clinical Trial |
title_full_unstemmed | A Novel Hair Restoration Technology Counteracts Androgenic Hair Loss and Promotes Hair Growth in A Blinded Clinical Trial |
title_short | A Novel Hair Restoration Technology Counteracts Androgenic Hair Loss and Promotes Hair Growth in A Blinded Clinical Trial |
title_sort | novel hair restoration technology counteracts androgenic hair loss and promotes hair growth in a blinded clinical trial |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9861617/ https://www.ncbi.nlm.nih.gov/pubmed/36675398 http://dx.doi.org/10.3390/jcm12020470 |
work_keys_str_mv | AT thordominik anovelhairrestorationtechnologycounteractsandrogenichairlossandpromoteshairgrowthinablindedclinicaltrial AT paganiandrea anovelhairrestorationtechnologycounteractsandrogenichairlossandpromoteshairgrowthinablindedclinicaltrial AT bukowieckijulia anovelhairrestorationtechnologycounteractsandrogenichairlossandpromoteshairgrowthinablindedclinicaltrial AT houschyarkhosrows anovelhairrestorationtechnologycounteractsandrogenichairlossandpromoteshairgrowthinablindedclinicaltrial AT køllestigfrederikt anovelhairrestorationtechnologycounteractsandrogenichairlossandpromoteshairgrowthinablindedclinicaltrial AT wylessaranyap anovelhairrestorationtechnologycounteractsandrogenichairlossandpromoteshairgrowthinablindedclinicaltrial AT duscherdominik anovelhairrestorationtechnologycounteractsandrogenichairlossandpromoteshairgrowthinablindedclinicaltrial AT thordominik novelhairrestorationtechnologycounteractsandrogenichairlossandpromoteshairgrowthinablindedclinicaltrial AT paganiandrea novelhairrestorationtechnologycounteractsandrogenichairlossandpromoteshairgrowthinablindedclinicaltrial AT bukowieckijulia novelhairrestorationtechnologycounteractsandrogenichairlossandpromoteshairgrowthinablindedclinicaltrial AT houschyarkhosrows novelhairrestorationtechnologycounteractsandrogenichairlossandpromoteshairgrowthinablindedclinicaltrial AT køllestigfrederikt novelhairrestorationtechnologycounteractsandrogenichairlossandpromoteshairgrowthinablindedclinicaltrial AT wylessaranyap novelhairrestorationtechnologycounteractsandrogenichairlossandpromoteshairgrowthinablindedclinicaltrial AT duscherdominik novelhairrestorationtechnologycounteractsandrogenichairlossandpromoteshairgrowthinablindedclinicaltrial |